From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared?
Carpenedo
Monica
M
Hematology and Bone Marrow Transplantation Unit, San Gerardo Hospital, University of Milan Bicocca, Via Pergolesi 33, Monza, Italy. mcarpenedo@katamail.com
Pogliani
Enrico Maria
EM
D001241:Aspirin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D011087:Polycythemia Vera / Q000150:complications / Q000235:genetics*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D001241:Aspirin
Lancet. 2005 Mar 19-25;365(9464):1054-61
15781101
Nature. 2005 Apr 28;434(7037):1144-8
15793561
N Engl J Med. 1974 Jun 13;290(24):1382
4827655
Curr Drug Targets. 2007 Feb;8(2):205-16
17305499
Cancer Cell. 2005 Apr;7(4):387-97
15837627
Intern Emerg Med. 2010 Oct;5(5):375-84
20237866
Hematology Am Soc Hematol Educ Program. 2008;:69-75
19074061
N Engl J Med. 2004 Jan 8;350(2):114-24
14711910
Intern Emerg Med. 2010 Oct;5(5):411-3
20607450
J Clin Oncol. 2005 Apr 1;23(10):2224-32
15710945
Exp Hematol. 2007 Jun;35(6):931-8
17533047
Haematologica. 2003 Jan;88(1):13-8
12551821
Blood. 1951 Apr;6(4):372-5
14820991
N Engl J Med. 2005 Apr 28;352(17):1779-90
15858187